text:
Chair: Olle Lindvall, University of Lund, Sweden Dr. Olle Lindvall is Professor of Clinical Neurology and Chairman of the Division of Neurology at the University Hospital, Lund, Sweden. He has served as Chairman of the Swedish Movement Disorder Society 1995-1998, Vice-Dean of the Medical Faculty at the University of Lund 1997-1999, elected member of the Board of the Swedish Research Council (medical division) 2001-2006, clinical coordinator in EU-sponsored integrated project EuroStemCell 2003-2007, and Chairman of the Steering Committee for Nordic Centers of Excellence in Molecular Medicine 2003-2007. He has received numerous Prizes and Awards. Dr. Lindvall is since 2004 member of the Board of the International Society for Stem Cell Research, and since 2005 member of the Board of Reviewing Editors for SCIENCE and member of the Scientific Advisory Board of the Michael J. Fox Foundation for Parkinson's Research.
Since 1983 Dr. Lindvall has headed the clinical neurotransplantation program in Lund. This program has pioneered cell replacement strategies and been the first to show proof-of-principle, i.e., that transplanted neurons can survive, grow, restore transmitter release, become functionally integrated, and give rise to clinically measurable improvements in the diseased, 50-60 year old human brain. Current research interests in Dr. Lindvall's laboratory are the development of stem cell-based approaches for cell replacement in Parkinson's disease and stroke, and of gene therapeutic strategies for neuroprotection and neuroregeneration in Parkinson's disease. Much focus is on the role and possible therapeutic relevance of neurogenesis from the adult brain's own neural stem cells in stroke and epilepsy.
Co-Chair: Insoo Hyun, Case Western Reserve University, Ohio, USA Insoo Hyun received his Ph.D. in Philosophy from Brown University and his B.A. and M.A. in Philosophy from Stanford. His scholarly interests include stem cell research ethics and policy, medical decision-making and informed consent, and the allocation of scarce health resources. In 2005, he was awarded a Fulbright Research Award by the U.S. Department of State to study the ethical, legal, and cultural dynamics of human research cloning in South Korea. In 2006 he chaired the Subcommittee on Human Biological Materials Procurement for the International Embryonic Stem Cell Guidelines Task Force, a multinational, multidisciplinary working group for the ISSCR (International Society for Stem Cell Research). Currently, Dr. Hyun is Chair of the ISSCR's Ethics and Public Policy Committee. Dr. Hyun's scholarly bioethics articles have appeared in Science, Nature, Cell Stem Cell, The Hastings Center Report, The Cambridge Quarterly of Healthcare Ethics, andThe Kennedy Institute of Ethics Journal, among others.
Subcommittee 1, Quality Control and Manufacturing, Chair: Mahendra Rao, Invitrogen, Washington, DC, USA Rao completed his medical training from Grant Medical College -India and subsequently obtained a Ph.D from California Institute of Technology- USA. He trained with Paul Patterson, David Anderson and Story Landis and his early work focused on the developing nervous system. Dr. Rao joined the faculty in the Department of Neurobiology and Anatomy where he lead a group that studied neuron-glial lineage diversification in the central nervous system. Soon after obtaining tenure Dr. Rao was recruited to the Laboratory of Neuroscience at the National Institute of Aging to lead the NIA's efforts on embryonic and neural stem cells. Dr. Rao currently leads the stem cell effort at Invitrogen as the Vice President-Research Stem Cells and Regenerative Medicine.
Dr. Rao holds faculty appointments at the National Center of Biological Sciences (India), the Buck Institute (CA), and JHU school of Medicine (MD). He has served as a consultant to several biotechnology companies, investment firms, governments and various regulatory and advisory agencies. Dr. Rao serves on the editorial Board of several journals including Stem Cells and Stem Cells and Development and the SAB of several granting agencies and University grants.
Dr. Rao's research focus continues to be identifying stem cell populations that could be used for discovery, screening and therapeutic purposes and developing the appropriate tools and reagents to enable a transition from the research domain to the clinic.
Subcommittee 2, Preclinical Testing, Chair: Giulio Cossu, Stem Cell Research Institute, Italy Giulio's research has focused on the development of pre-clinical models of cell therapy for muscular dystrophy. His lab has characterized a population of mesoderm progenitors from the blood vessels of fetal and adult mammalian tissues, named mesoangioblasts. These cells have been delivered systemically to dystrophic mice and dogs and caused amelioration of muscle structure and function. Based on these results we are now planning a phase I/II clinical trial in pediatric patients affected by Duchenne muscular dystrophy.
Giulio Cossu is a member of the Directory Board of the Italian Radical Party and of the Luca Coscioni Association for freedom of research.
Subcommittee 3, Clinical Trials, Chair: Ira Fox, Nebraska Medical Center, Nebraska, USA Ira Fox, M.D is the Charles W. McLaughlin Professor of Surgery and former Senior Associate Dean for Research and MD-PhD Program Director at the University of Nebraska Medical Center. His major research interests involve the study of experimental therapies for liver disease, including liver assist devices, liver cell transplantation, and liver stem cells. His laboratory examines the efficacy of transplanting primary and conditionally immortalized hepatocytes in rodents, and studies the immunologic barriers to cross-species transplantation in rodents and primates. His laboratory also studies differentiation of mouse and human embryonic stem cells into liver cells. He has initiated clinical trials involving extracorporeal liver perfusion to treat patients with acute liver failure, and has demonstrated successful correction of liver-based metabolic deficiencies in newborns and young children by transplantation of isolated liver cells.
Subcommittee 4, Social Justice, Chair: Laurie Zoloth, Northwestern University, Illinois, USA Laurie Zoloth is Director of the Center for Bioethics, Science and Society and Professor of Medical Ethics and Humanities at Northwestern University, Feinberg School of Medicine, and Professor of Religion and a member of the Jewish Studies faculty at Northwestern University, Weinberg College of Arts and Science. In 2005, after two terms of service on NASA's National Advisory Council, she received the NASA Public Service Medal. In 2001, she was President of the American Society for Bioethics and Humanities. Professor Zoloth is the chair of the HHMI Bioethics Committee and is a founding board member of the International Society for Stem Cell Research, and of the Society for Neuroethics, on NASA's first Planetary Protection Advisory Committee, and on the boards of several national organizations. In 2007 she was nominated to the Institute of Medicine. She is the author of The Ethics of Encounter: A Jewish Perspective on Health Care Justice, and is co-editor of two books on religion, science, and ethics. In 2000, she was co-PI for an NIH ELSI grant on identity, ethnicity, and citizenship after the Human Genome Project. She has published extensively in the areas of ethics, family, feminist theory, religion and science, Jewish Studies, and social policy. Her current research projects include work on the emerging issues in medical and research genetics and on the ethical issues in stem cell research, and her research interest in distributive justice in health care continues.
Members: Lars Ahrlund-Richter, Karolinska Institute, Sweden Lars Ährlund-Richter, Ph.D. is Professor of Molecular Embryology at the Dept. of Woman and Child Health, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden. L.Ä.R. received a MSci in Biology at Stockholm University (1975) and a PhD at the Karolinska Institute (1983). Following a period as post doctoral fellow at the National Institute of Medical Research, London, UK, he became associate Professor in Tumor Immunology (1990), Reader of Molecular Embryology (2000) and Professor of Molecular Embryology (2001), at the Karolinska Institute.
L.Ä.R. was founder and head of the Karolinska Institute core facility "Mammalian Embryo and Genome research", and in this role 1996-2006 a member of the Board of Directors of the European mouse mutant archive (EMMA), Monterotondo, Italy; member of the Committee on ES cells in the Federation of International Mouse Resources (FIMRE) (2005-2006) and member of Ethical Committee on animal experimentation, District Court of Huddinge, Sweden (2002-2006). He was scientific consultant at the laboratory of the IVF unit, Sophia Hemmet Hospital, Stockholm (1993-1994); of the IVF unit Huddinge University Hospital, Stockholm (1994-1998); and coordinator of the Karolinska Institute Network on "Derivation, characterization and banking of human embryonic stem cells" 2003-2005. This network has derived and characterized a series of hESC lines. Since 2005 L.Ä.R. is a member of the ISSCR Stem Cell Standards Committee and was 2006 a member of the ISSCR task force; "Guidelines for the conduct of human embryonic stem cell research". Recent research include xeno-transplantation of hESC with normal and abnormal karyotypes, with emphasis on stem cell derived microenvironments and possible applications in tumour research.
Elena Cattaneo, University of Milan, Italy Elena Cattaneo is full professor of Pharmacology at the University of Milano. She is the director of the "Laboratory of stem cell biology and pharmacology of neurodegenerative diseases" at the Department of Pharmacological Sciences (www.cattaneolab.it) and co-founder and first appointed Director of UniStem, the Centre for Stem Cell Research of the University of Milano (www.unistem.it). The main research themes of her lab are neural stem cell biology and the molecular pathophysiology of Huntington's Disease.
Marina Cavazzana-Calvo, INSERM, France Marina Cavazzana-Calvo obtained a MD at the University of Padua School of Medicine (Italy) in 1983 and a PhD in Blood Cell Biology at Paris VII University (France) in 1993. In 2000 she became Professor of Hematology at Paris V University, and Head of the Departement of Biotherapy at Necker Children's Hospital, Paris, France, in 2003. Her major research interests involve the setting up of new therapeutic approaches for inherited diseases of the hematopoietic system.
Her group studies the means to improve the clinical results of hematopoietic stem cell transplantation cross HLA-barriers in humans, and the differentiation of mouse and human stem cells towards lymphocyte lineages. She has initiated several clinical trials based on the use of ex vivo gene modified cells to treat patients with inherited disorders, the preliminary clinical results of which are encouraging. This work was rewarded by the American Society of Hematology (Award on Clinical Research in Gene Therapy in 1999) and by the French Academy of Sciences (Special Medical Award in 2000 and Jean-Pierre Lecocq Award on Gene Therapy in 2004). She is a member of the Transatlantic Gene Therapy Consortium since 2005, of the American Society of Gene Therapy Hematopoietic Committee and Ethics Committee since 2006, and an invited member of the Blood Editoral Board since 2008.
George Q. Daley, Children's Hospital Boston, Massachusetts, USA George Q. Daley, M.D., Ph.D. is Associate Professor of Hematology/Oncology at Children's Hospital Boston and Biological Chemistry and Molecular Pharmacology at Harvard Medical School, and an investigator of the Howard Hughes Medical Institute. He is Associate Director of the Stem Cell Program at Children's Hospital, a member of the Executive Committee of the Harvard Stem Cell Institute, and currently President of the International Society for Stem Cell Research. Dr. Daley received his bachelor's degree magna cum laude from Harvard University, a Ph.D. in biology from MIT, and his M.D. summa cum laude from Harvard Medical School. He is a fellow of the American Association for the Advancement of Science, a member of the American Society for Clinical Investigation, and has received the NIH Director's Pioneer Award, the Judson Daland Prize from the American Philosophical Society, and research awards from Harvard Medical School, the National Institutes of Health, the New England Cancer Society, the Burroughs-Wellcome Fund, the Edward Mallinckrodt, Jr. Foundation, and the Leukemia and Lymphoma Society of America.
Michele de Luca, University of Modena, Italy Michele De Luca, MD is Full Professor of Biochemistry, Director, Centre for Regenerative Medicine and Interdepartmental Center for Stem Cells and Regenerative Medicine, University of Modena and Reggio Emilia, and Scientific Director of Holostem Terapie Avanzate S.r.l.
Michele played a pivotal role in epithelial stem cell-mediated cell therapy and gene therapy. Beside his pioneering work on the use of human epidermal stem cell cultures in life-saving treatment of massive full-thickness burns and in repigmentation of stable vitiligo and piebaldism, he, and his prinicpal collaborator Graziella Pellegrini, were first in establishing human urethral epithelia stem cell cultures aimed at urethra regeneration in posterior hypospadias and human limbal stem cell culture aimed at corneal regeneration in patients with chemical burn-dependent corneal destruction. This latter treatment leads to recovery of vision in patients with poor alternative therapy. Michele is currently coordinating the first (successful) ex-vivo epithelial stem cell-mediated gene therapy clinical trial for the gene therapy of genetic skin diseases as Junctional Epidermolysis Bullosa.
Claude Gerstle, MD, USA Dr. Gerstle had been dedicated to patient care for over 30 years before he became quadriplegic in a bicycle accident in August, 2003. Transformed from a knowledgeable physician to a questioning patient, he wondered if promising new stem cell research could cure his damaged spinal cord. He just finished the documentary, "Travels with My Dad" in search of that answer. In his role as the chief interviewer of the film, he tracked down the thinkers, the politicians, the crusaders and the naysayers in an effort to understand the potential of this exciting area of biomedical research and why a political quagmire in the United States is stalling its progress.
Prior to his accident, he founded a full service ophthalmologic clinical practice in New Jersey from 1975-2003 that focused on the diagnosis, management and surgical/medical treatment of ocular diseases. He is a graduate of the Massachusetts Institute of Technology and New York University Medical School. For the last four years he has been a trustee of MIT's Corporation.
He works on his physical rehabilitation for three hours daily and is becoming a better bridge player.
Bob Goldstein, JDRF, New York, USA Robert A. Goldstein, M.D., Ph.D. is the Chief Scientific Officer for JDRF where he is responsible for guiding national and international research programs of the foundation. He received his undergraduate degree from Brandeis University, his medical degree from Jefferson Medical College, his Ph.D. (in Microbiology/Immunology) from George Washington University and his MBA from the Stern School of Business, New York University. He is a Fellow of the American College of Physicians, the American College of Chest Physicians and the American Academy of Allergy, Asthma and Immunology. Before joining JDRF in 1997, he was Director of the Division of Allergy, Immunology and Transplantation at the National Institute of Allergy and Infectious Diseases of the US National Institutes of Health (Dr. Anthony Fauci, Director).
He has authored more than 50 scientific publications and is a reviewer for scientific journals including the American Journal of Respiratory and Critical Care Medicine, Annals of Internal Medicine, Journal of the American Medicine Association, and the New England Journal of Medicine. He has served and continues to serve on many advisory committees, including the UK National Institute for Health Research Advisory Board, the US Food and Drug Administration Science Board, and the Agenxia Italiana del Farmaco. He has participated in National Academy of Sciences workshops on Embryonic Stem Cell Research, and on California Institute of Regenerative Medicine advisory committees. He has represented JDRF at the International Stem Cell Forum since its inception in 2003.
Göran Hermerén, Lund University, Sweden Göran Hermerén, Professor of Medical ethics, Lund University, Sweden since 1991, professor of philosophy, Lund University 1975. Previously visitng fellow at Princeton University, University of Michigan and Trinity College, Dublin, published books and papers on aesthetical and ethical problems raised by research in medicine. Partner in several EU-funded projects on stem cell research. Chairman of the advisory board of the German reference centre for ethics in the life sciences DRZE (Bonn). President of the European Group on Ethics in Science and New Technologies (Brussels).
Göran Hermerén, Professor of Medical ethics, Lund University, Sweden since 1991, professor of philosophy, Lund University since 1975. Previously visitng fellow at Princeton University, University of Michigan and Trinity College, Dublin. Has published books and papers on aesthetical and ethical problems in international periodicals. Partner in several EU-funded projects on stem cell research. Partner in several research projects funded by the EU. Member of the National Council on Medical Ethics in Sweden since its start. Chairman of the ethics committee of the Swedish Research Council (Stockholm), chairman of the advisory board of the German reference centre for ethics in the life sciences DRZE (Bonn) and President of the European Group on Ethics in Science and New Technologies (Brussels).
Katherine High, University of Pennsylvania, Pennsylvania, USA Katherine High graduated from Harvard with a degree in Chemistry before carrying out her M.D. studies at the University of North Carolina (UNC) School of Medicine. She then trained as a Fellow in the Hematology Section at Yale University School of Medicine for four years, before returning to UNC as a faculty member in the Department of Medicine and the Curriculum in Genetics. Later, she moved to Philadelphia to her present concurrent positions as William H. Bennett Professor of Pediatrics at the University of Pennsylvania School of Medicine, Investigator, Howard Hughes Medical Institute, and Director, Center for Cellular and Molecular Therapeutics at The Children's Hospital of Philadelphia.
Dr. High's research interests have focused on the molecular genetic basis of blood coagulation. The work involves structure-function studies and gene expression analysis of factors involved in the coagulation process. More recently, her work has focused on development of novel therapeutics for hemophilia, which includes completion of clinical trials of an AAV-mediated, liver-directed approach.
Dr. High has published over 100 scientific articles, including one of the first reports of gene transfer in patients with hemophilia B. She is an active member and Councillor of the American Society of Hematology, serves on the National Heart, Lung, and Blood Institute Advisory Council, and Past President of the American Society of Gene Therapy. Dr. High is an associate editor of the Journal of Clinical Investigation, and also serves on the editorial boards of Blood, Human Gene Therapy and Molecular Therapy.
Hyun Ok Kim, Yonsei University, Korea Hyun Ok Kim, M.D., Ph.D. is a professor in the Department of Laboratory Medicine at Yonsei University College of Medicine, Seoul, Korea. She is presently the medical director in Transfusion Medicine and the director of the Severance Hospital Cell Therapy Center.
Dr. Kim received her M.D. degree at Yonsei University in 1982. She then completed her intership and residency in the Department of Clinical Pathology at Severance Hospital, affiliated with Yonsei University Medical Center in 1982-1985, and received her Ph.D. from Yonsei University in 1990. Furthermore, she trained as a post-doctoral research fellow at Johns Hopkins Medical Institute in Baltimore, USA. Subsequently, she became professor in the Department of Laboratory Medicine at Yonsei University College of Medicine in 2004.
Dr. Kim serves as a member in multiple associations, including the Korean Society of Blood Transfusion, the Korean Society of Laboratory Medicine, the Korean Society of Hematology, American Association of Blood Transfusion (AABB), Internal Society of Celllular Therapy (ISCT), International Society of Blood Transfusion (ISBT). She has also been the academic consultant of Korean Red Cross Blood Research Center from 1989, served as a council member of Nation Blood Safety and Control Advisory Committee since 2004, and participated in the Cell Therapy Advisory Committee in association with the Korean FDA since 2005. She also acted as the vice director of Blood Safety Improvement TFT, Korea, and was elected to be the Chairman of the Board in the Korean Society of Blood Transfusion in 2005-2008.
She is currently studying various areas in transfusion medicine and cellular therapy. Her interests include the establishment of guidelines for clinical application involving human participation in transfusion and cellular therapy, which are collaborative projects with the KFDA. She is also actively studying human cord blood stem cells and their differentiation into red blood cells, hepatocytes, dendritic cells, etc. Her projects include establishment of methods designed to amplify these cells for clinical application.
HP Lee, National University of Singapore, Singapore Dr LEE Hin-Peng is Professor and former Head (1987-2001) in the Department of Community, Occupational and Family Medicine, National University of Singapore. He was also Vice-Dean of the Medical Faculty (1985-1997) and Chairman of the Specialist Training Committee in Public Health (1987-2004). His main teaching and research interests are in non-communicable disease epidemiology, especially cancer epidemiology and prevention. He is co-Principal Investigator of the NUS-UM Chinese Health Study (The Singapore Cohort Study) and Chairman of the Singapore Cancer Registry. He graduated from the University of Singapore's Medical School in 1971, obtained the M.Sc. (Public Health) and also the Fellowship of the UK Faculty of Public Health (FFPH) of the Royal Colleges of Physicians. He has also done postgraduate work in the UK and USA. In addition, he was on the Singapore Medical Council (1989-2004) and continues on the Board of St Luke's Hospital, where he is Chairman of St Luke's Eldercare. He was also Master of King Edward VII Hall at National University of Singapore (1996-2005). In 2003, he was appointed Chairman of the NUS Institutional Review Board (IRB), and in 2005 was also Chairman of the Working Group for the Health Services Research Unit of the School of Medicine. Recently, he was appointed Deputy Chair of the Singapore Bioethics Advisory Committee. He received the Public Service Star from the Government in 2005.
Ephrat Levy-Lahad, Israel Ephrat Levy-Lahad, MD is director of the Medical Genetics Unit at Shaare Zedek Hospital in Jerusalem, Israel and associate professor of Internal Medicine and Medical Genetics at the Hebrew University-Hadassah Medical School. She received her MD degree from Hebrew University-Hadassah Medical School (1989; Jerusalem, Israel) trained in Internal Medicine at Shaare Zedek Medical Center and in Medical Genetics at the University of Washington in Seattle. She is board certified in Internal Medicine (Israel) and in Clinical and Clinical Molecular Genetics (USA and Israel).
Dr. Levy-Lahad's clinical laboratory includes a large preimplantation diagnosis service, and cancer genetics diagnostics. Her research laboratory focuses on genetic epidemiology of breast cancer, in particular BRCA1 and BRCA2, and genetic and environmental modifiers of penetrance of these genes.
Dr. Levy-Lahad is a current member of Israel's National Bioethics Committee, Israel's National IRB Committee for Genetics and Reproductive studies, and of UNESCO's IBC (International Bioethics Committee).
Lingsong Li, Peking University, China Lingsong Li, born in 1962, graduated from Bethune University of Medical Science with his M.D. He received his Ph.D. major in Molecular and Cellular Biology from the University of Washington. He worked as a senior research fellow at Stanford University before joining Peking University. He is now the Yazhi-river Professor and Director of Peking University Stem Cell Research Center. He also served as the Chairman of the Department of Cell Biology, Peking University Health Science Center. In addition, he is the principle investigator and the chief scientist for the national "973" and "863"stem cell project.
His research is addressing the molecular mechanism in regulation of ES cell self-renewal by a global comparison of ES cells versus PGC cells. He also interested in the PAX6-SOX2 interaction in regulation of neural stem cell biology.
Bernard Lo, UCSF, California, US Dr. Bernard Lo is Professor of Medicine and Director of the Program in Medical Ethics at UCSF. He is National Program Director for the Greenwall Faculty Scholars Program in Bioethics, a career development award for junior faculty members. He is co-chair of the Standards Working Group of the California Institute of Regenerative Medicine, which will recommend regulations for stem cell research funded by the state of California under Proposition 71. He is also a member of the California Human Stem Cell Research Advisory Committee, which will recommend guidelines for stem cell research carried out in California funded from other sources. He chairs the UCSF committee on Gamete, Embryo, and Stem Cell Research, which oversees all such research. He previously served on the 1994 NIH Advisory Board on Research on Human Embryos and on the California Advisory Commission on Human Cloning (1998-2002).
He also serves on the Data and Safety Monitoring Committees for diabetes prevention trials at NIDDK and a HIV vaccine trial at NIAID. He is a member of the Ethics Working Group of the NIH-sponsored HIV Prevention Trials Network, which carries out clinical trials in developing countries. He is co-Director of the Policy and Ethics Core of the Center for AIDS Prevention Studies at UCSF, which provides technical advice and consultation to researchers carrying out clinical research, including research in resource-poor nations. He is a member of the steering committee of the UCSF K-12 Roadmap program that provides training in interdisciplinary clinical research.
He is a member of the Institute of Medicine (IOM) and serves on the IOM Council. He chairs an NAS/IOM committee on conflicts of interest in medical research, medical education, clinical care, and practice guideline development. He served on the National Bioethics Advisory Committee (1996-2001) and served the Recombinant DNA Advisory Committee at NIH. He developed a course on Responsible Conduct of Research at UCSF that 120 postdoctoral fellows and junior faculty take each year. He also carries out research on ethical issues in human participants research and other topics in bioethics.
Dan Marshak, PerkinElmer, Massachusetts, USA Daniel R. Marshak, Ph.D. is Vice President and Chief Scientific Officer for PerkinElmer, Inc. (NYSE:PKI). Dr. Marshak is responsible for setting the strategic direction of PerkinElmer's research and development functions, and helping drive its growth strategies in the emerging areas of personalized medicine and predictive diagnostics. Most recently, Dr. Marshak was Vice President & Chief Technology Officer, Biotechnology, for Cambrex Corporation (NYSE:CBM), setting strategy in biosciences and participating in corporate and commercial activities. Dr. Marshak joined Cambrex in 2000, and through 2001 led R&D worldwide for the Bioscience sector. Concurrently, Dr. Marshak also holds an appointment as Adjunct Associate Professor at The Johns Hopkins University School of Medicine, Baltimore, Maryland.
Previously (1994-2000), Dr. Marshak was Senior Vice President and Chief Scientific Officer for Osiris Therapeutics, Inc., a U.S. biotechnology company developing adult stem cell products for the regeneration of diseased or damaged tissues. He was previously (1986-1995) Senior Staff Investigator at the Cold Spring Harbor Laboratory, Long Island, New York, where he and the members of his laboratory conducted research in signal transduction, cellular growth control, and differentiation. Dr. Marshak was concurrently (1987-1994) Assistant Professor, School of Medicine, State University of New York at Stony Brook, where he taught graduate biochemistry.
Dr. Marshak received his B.A. from Harvard University, Cambridge, Massachusetts, in Biochemistry & Molecular Biology, and his Ph.D. from The Rockefeller University, New York City, in Biochemistry & Cell Biology. He did postdoctoral research in Pharmacology at Vanderbilt University School of Medicine, Nashville, Tennessee, and at the National Institutes of Health, Bethesda, Maryland. Dr. Marshak has received several awards for scientific and academic achievements. He is also an inventor on six issued U.S. patents.
Dr. Marshak has extensive research experience in the growth control of human cells. Dr. Marshak is author of more than 100 scientific publications, including one textbook, and he has been editor of five monographs. The most recent monograph, Stem Cell Biology, was published in 2001 by The Cold Spring Harbor Laboratory Press.
Angela McNab, Department of Health, United Kingdom Angela has been seconded to the Department of Health for six months to work as Director of Public Health and Performance for the Chief Medical Officer.
Angela McNab started her career in the NHS as a clinician before moving into general health management. She is a qualified Speech and Language Therapist. She held a variety of senior positions in Community and Mental Health Trusts
In 1999 Angela joined the Department of Health to lead on the development of the National Sexual Health and HIV Strategy. This gave her experience of working in a very high profile and sensitive field.
She returned to the NHS as Chief Executive of a newly formed North East London Primary Care Trust leading that organisation to achieve the highest performance rating across London at the end of its first year.
In 2002 Angela moved into her current role as Chief Executive of the Human Fertilisation and Embryology Authority and in 2005 became the first Chair of the European Assisted Conception Consortium.
Megan Munsie, Australian Stem Cell Centre, Australia Dr Megan Munsie has recently joined the Australian Stem Cell Centre as the Director of Government Affairs and Policy. The Australian Stem Cell Centre is Australia's Biotechnology Centre of Excellence. The Centre's principal objective is to integrate a national multi-institutional research and discovery program to develop treatments for serious disease through the application of stem cells and related technologies. Megan's role within the Centre is to advise on scientific strategy, provide oversight of ethics procedures and policy, facilitate new collaborative ventures and liaise with researchers within and external to the organisation.
Previously, Megan was the Australian Scientific Development Manager of the UK listed biotechnology company, Stem Cell Sciences, where she was responsible for the coordination and integration of the Australian group's research activities within the SCS network and with local and international collaborators.
Megan is fascinated by all aspects of stem cell biology with a particular interest in derivation and differentiation of embryonic stem cells. Megan is a member of the successful Stem Cell Sciences team that derived the MEL series of human embryonic stem cell lines in a NHMRC licensed project with Melbourne IVF and the Australian Stem Cell Centre. She has also been involved in an innovative strategy to derive purified populations of mouse neuronal cells for use in drug screening and development.
In 2000, Megan published the first proof-of-principle for 'therapeutic cloning'. In this ground breaking paper she demonstrated that it was possible, through the technique of somatic cell nuclear transfer (SCNT), to reprogram the nucleus from an adult mouse cell back to an 'embryonic' state. By generating an embryonic stem cell line from the resulting nuclear transfer 'embryo', she provided the first evidence that the generation of individual-specific stem cell lines was feasible.
Megan has been actively involved in petitioning for reform to the current Commonwealth legislation that would allow Australian scientists the opportunity to use SCNT to generate disease-specific cells for disease modelling and drug discovery.
Megan is skilled in all aspects of assisted reproductive technology with over twelve years experience as an embryologist in several IVF practices in Australia. Megan completed her undergraduate degree at the Queensland University of Technology and has received a Masters of Reproductive Sciences and Doctorate of Philosophy from Monash University.
Hiro Nakauchi, University of Tokyo, Japan Hiro Nakauchi obtained a M.D. from Yokohama City University School of Medicine and a Ph.D. in immunology from University of Tokyo Graduate School of Medicine. He isolated CD8 genes during his post-doc period at the Laboratory of Prof. Leonard Herzenberg at Stanford University. After coming back to Japan, he started working on hematopoietic stem cells in his laboratory in RIKEN. In 1994, he became Professor of Immunology in the University of Tsukuba where he determined the phenotype of mouse hematopoietic stem cells and established an in vivo clonal analysis system. Since April 2002, he has been a Professor of Stem Cell Therapy in the Institute of Medical Science at the University of Tokyo. Goals of his work are to clarify the mechanism of stem cell self-renewal and to contribute to the cell/gene therapy and regenerative medicine.
Carlos Simon, Valencia Stem Cell Bank, Spain Obtained his MD degree with award of excellence from Valencia University in 1985 and is Board Certified Obstetrics and Gynecologist after completing his residency in Obstetrics & Gynecology in the University Clinical Hospital of Valencia from 1986 to 1991 and Doctor after passed his Doctoral Thesis in Valencia University. Founded by a grant from the Spanish Government, Dr. Simon completed a postdoctoral research fellowship on Reproductive Immunology in the Department of Ob/Gyn at Stanford University, California USA, from 1991 to 1994.
Since 1994 he has been Associate Professor in the Department of Pediatrics, Obstetrics and Gynecology, at Valencia University Spain, and Scientific Director of the Instituto Valenciano de Infertilidad Foundation (FIVI). In 2004, He has been appointed as Head of the Valencia Stem Cell Bank and Coordinator of Regenerative Medicine Príncipe Felipe Research Centre, a private non-profit organism devoted to stem cell derivation and research. In 2007 he obtains the first place in the national examination to become Full Professor at the University of Valencia. Research in his laboratory focuses on human embryonic implantation, uterine receptivity, human embryonic and adult stem cells leading to the publication of over 232 per review papers and 12 books. Since 2001, his background on Reproductive Medicine led him to the research on human embryonic stem cells in Spain. His group derived the first two clinical grade embryonic stem cell lines in Spain, named Valencia 1 and 2 (VAL1 and VAL2) and recently, his lab derived and published Val-3, -4, -5. Awarded by the Spanish Fertility Society in 1991, 2001 and 2003; Society for Gynaecological Investigation (SGI) (President Poster Award), in 1993 (President's Presenter Awards) 2002, and the Society of Reproductive Endocrinologist of the American Society for Reproductive Medicine (ASRM) in 1993, 1995, 1997, 1999, 2001 and 2005. Member of the Editorial Board of several international publications including Human Reproduction and Reproductive Biomedicine on line. Dr. Simon has served as member in the research committees of international societies including SGI, ASRM, ESHRE and IFFS and the World Health Organization as member of the HRP Scientific and Ethical Review Group since 1998.
Alok Srivastava, Christian Medical College, India Alok heads the Department of Haematology at CMC, Vellore which provides the largest comprehensive haematology service in India that also includes the largest stem cell transplantation program in the country. He is also responsible for establishing the Center for Stem Cell Research in this institution. This is a joint venture of the Department of Biotechnology, Government of India with CMC, Vellore, first of its kind in the country, and is aimed at developing translational research with stem cells. As co-chair of the national task force for stem cell research in India, he is also involved with planning and supporting this field in the country. He is involved with both basic research and clinical trials with stem cells. His other research interest is in haemostasis, where he chairs the FVIII / IX subcommittee of the Scientific and Standardization committee of the International Society on Thrombosis and Haemostasis.
Jeremy Sugarman, Johns Hopkins University, Maryland, US Jeremy Sugarman, MD, MPH, MA is the Harvey M. Meyerhoff Professor of Bioethics and Medicine, Professor of Medicine, Professor of Health Policy and Management, and Deputy Director for Medicine of the Berman Institute of Bioethics at the Johns Hopkins University. Dr. Sugarman conducts both theoretical and empirical research in medical ethics. His work concentrates on informed consent, research ethics, and the ethical issues associated with emerging technologies. He is the author of over 150 publications in peer-reviewed journals. In addition, he has edited or co-edited four books (Beyond Consent: Seeking Justice in Research; Ethics of Research with Human Subjects: Selected Policies and Resources; Ethics in Primary Care; and Methods in Medical Ethics). Dr. Sugarman is a contributing editor for IRB, and is on the editorial boards of Accountability in Research, the American Journal of Bioethics, Clinical Trials, and Theoretical Medicine and Bioethics. Dr. Sugarman serves on the Scientific and Research Advisory Board for the Canadian Blood Service and the Maryland Stem Cell Research Commission. He is currently Chair for the Ethics Working Group of the HIV Prevention Trials Network, the Ethics Officer for the Resuscitation Outcomes Consortium, and Co-Chair of the Johns Hopkins' Embryonic Stem Cell Research Oversight Committee. Dr Sugarman is a member of the American Society of Clinical Investigation and a Fellow of the American Association for the Advancement of Science, the American College of Physicians, and the Hastings Center.
Patrick Taylor, Children's Hospital Boston, Massachusetts, USA Patrick L. Taylor is Deputy General Counsel and Chief Counsel, Research Affairs, at Children's Hospital Boston, in a position focused mostly on legal and policy issues in biomedical research, biotechnology
(including intellectual property, start-ups and licensing), research ethics, privacy, human subject protection and compliance. He has had a diverse career in representing and counseling not-for-profit, for-profit, and government clients involved in health, biotechnology, medical research, and human services. He received his BA from the University of Wisconsin-Madison (Phi Beta Kappa, highest honors), and received his JD with honors from Columbia University Law School. He also holds a faculty position as a Lecturer at Harvard Medical School. His research and writing focus on issues in research ethics, academic-industry collaborations, conflicts of interest, stem cell research, privacy, and the electronic medical record network. His writings have appeared in Science, Nature Biotechnology, Cell Stem Cell, Academic Medicine, Drug Development, and Science and Engineering Ethics, as well as numerous legal journals.
Anna Veiga, Barcelona Stem Cell Bank, Spain Born in Barcelona in 1956. Graduated in Biology (1974-1979). Ph.D. in Biology (Cum Laude). Universidad Autonoma de Barcelona 1991. IVF laboratory Director (1982-2004), Scientific Director of Servei de Medicina de la Reproducción, Dpto Obstetricia y Ginecología, Institut Universitari Dexeus (2005). Director of the Barcelona Stem Cell Bank . Centre for Regenerative Medicine in Barcelona. (May 2005) Coordinator of the Msc Master course on Reproductive Biology and ART, Universitat Autónoma de Barcelona since 1998. Associate professor of Departament de Ciències Experimentals i de la Vida, Universitat Pompeu Fabra since 2002. Founder and President of the Spanish Embryologist Society (ASEBIR) (1993 –2003). Member of the Alpha Scientists in Reproductive Medicine Executive committee (1998-2002). Member of the Executive committee of the European Society for Human Reproduction and Embryology (ESHRE) (2001- 2005). Chairman of the Special Interest Group in Stem Cells. Scientific Coordinator of European Human Embryonic Stem Cell Registry(EU hESCreg)(2006- ). Actively involved in Assisted Reproductive Technologies (ART) since the early times of In Vitro Fertilization, she has published many articles in national and international journals and book chapters related to the field. She has participated in national and international meetings as well as in the diffusion of ART in Spain. Actively involved in Bioethics, she is the director of the "Bioethics in Biomedical Research" Group, Comite Consultiu de Bioetica de Catalunya. Her main areas of interest are Clinical Embryology, Reproductive Genetics, Embryonic Stem Cell research and Bioethics. Scientific Director of the Reproductive Medicine Service. Institut Universitari Dexeus. Barcelona Director of Barcelona Stem Cell Bank. Centre for Regenerative Medicine CMR[B]. Parc de Recerca Biomedica de Barcelona.


text:
It's not a good week to be called Ashley. There never has been.
Messrs Cole and Young are the latest plums to be put on the spot over their penalty-taking prowess following England's Euro 2012 exit.
Young complained to pals that his preparation had not been right - he hadn't dived to win the pen in the first place.
In a normal match, a footballer is about 1-4 to convert a penalty, or 1-5 if the keeper is David De Gea. If it's a player in a penalty shoot-out, those odds drift to 4-11. If it's an England player in a penalty shoot-out, you'll likely get evens.
Seven defeats in eight shoot-outs, our record now reads. Short-sighted gunslingers in Boot Hill had a better success rate.
Hills offer 8-1 for England not to win a penalty shoot-out until after Euro 2020 - and that covers four tournaments, three of which we probably won't qualify for.
Young's penalty hit the bar - ironic because he failed spectacularly to hit any other heights during the tournament.
How bad was he? Well, England fans started yearning for Stewart Downing - that's how bad.
His Manchester United team-mate Wayne Rooney was even worse.
I'm told the granny magnet had his own fitness coach in the run-up to Euro 2012 but I can only assume it was Eric Pickles.
Rooney looked so slow he'd struggle to beat one of his racehorses.
Shrek has confessed that the night before matches he lies awake going through what might happen the next evening - on Saturday night, probably not for the first time, he dreamed of being dominated 24 hours later by a long-haired old-timer called Andrea.
Our problems started when Steven Gerrard went missing and Andy Carroll didn't. Gerrard is 6-4 with Ladbrokes to be skipper for the first match of the World Cup finals, for which England are 1-6 to qualify.
Roy Hodgson, 5-6 still to be boss then, is 20-1 to name the same line-up that started against Italy. Not even he could be that thick.
Hodgson paid a price for the tactics he used against the Italians. It was safety first. And second. And third. He has turned the Three Lions into the Red Lion.
Semi-final betting (Hills): 7-2 Portugal v 10-11 Spain (11-5 draw); 5-6 Germany v 19-5 Italy (11-5 draw). Winner: 13-8 Spain, Germany, 11-2 Portugal, Italy.

subset: commoncrawl


text:
On June 10 the General Council of the Assemblies of God sent 45 students from Evangel
University, Central Bible College, and the Assemblies of God Theological Seminary to the
Balkans for a two-month Pentecostal Practicum. After the first week of staying at the
Osijek Evangelical Theological Seminary the group split into 10 teams that were sent to
different cities throughout Croatia and Bosnia to work in various ministries.
Realities of poverty and prejudice pierced into the hearts of some teams who visited
Gypsy villages that had no running water or electricity. Many villagers lack sufficient
medical care, have no means of transportation, and are uneducated. They are outcast by
the surrounding people groups. Although the Croatians, Serbians, and Muslims wage war
among one another, they all unite in their feelings of contempt toward the Gypsies.
Updated: Thursday, August 7, 2003 3:27 PM


text:
What is a hospitalist?
Hospitalists are doctors, physician assistants and nurse practitioners who specialize in providing care for hospitalized patients.
Who will be in charge of my care while I am in the hospital?
Many primary care physicians no longer visit patients in the hospital, so they entrust hospitalists to care for you while you are in the hospital. Hospitalists also care for patients who do not have a primary care provider and partner with surgeons and other specialists to ensure your general medical needs are met.
What is the role of a hospitalist?
Hospitalists work solely in the hospital and do not run a traditional clinical practice. This allows them to be more available to patients and their families during their stay in the hospital. Because their specialty is hospital-based care, a hospitalist is able to stay current with the standards of care in a hospital setting. Hospitalists are able to focus their ongoing education on the newest trends in hospital care. This allows them to deliver up-to-date, high-quality care.
A hospitalist is available to patients around the clock.
What can I expect from the hospitalist?
What are the benefits of having a hospitalist manage my care?
© 2017 KentuckyOne Health • 200 Abraham Flexner Way, Louisville, KY 40202


text:
Contrary to some suggestions in the market, the minutes from the Reserve Bank of Australia's latest policy meeting do not suggest to me the decision to cut interest rates this month was a particularly close call.
What's clear is that the board decided the case for another cut in interest rates was likely in place. According to the minutes: "The board considered whether to respond to this case in the near term or wait for further information. On balance, members saw merit in reducing the cash rate at this meeting."
So the decision to cut seems more a case of not "if" but "when". In my experience, the RBA usually acts earlier rather than later when the case for a change in interest rates is fairly clear unless there is some important new information just around the corner.
To that end, the often volatile quarterly national accounts – which were released a day after the latest meeting – do not qualify, as the bank already had enough information from partial indicators and industry liaison to suggest the economy had softened.
The fact that the next policy meeting was not until February added to the case for the bank to act sooner rather than later.
That said, it's worth noting that the bank chose to cut interest rates despite acknowledging that global economic conditions, particularly in China, had improved at the margin. Indeed, this was the first cut in interest rates since the cycle began in late 2011 that seemed to more closely reflect domestic rather than international factors.
Of most concern to the RBA these days is not Europe, China or even America's fiscal cliff but rather that Australia's mining investment boom looks likely to peak a lot earlier than expected, while interest rate cuts to date have had only a modest positive effect on the non-mining sector due to a combination of business and consumer caution, fiscal consolidation and the high Australian dollar.
Superimposed on this slowdown in the real economy is an even greater slowdown in national incomes, due to the fall in export prices.
Judging by the tone of RBA governor
What's more, Stevens implied that the growth transition from mining to non-mining next year may not be smooth, noting "we're not going to be able to absolutely guarantee seamlessly every handover from one source of demand to another".
Since around August last year, I've held the view that the official cash rate would likely drop to 2.5 per cent by mid-2013, due to the mining investment boom peaking and the lethargic response of the non-mining sector to the lower interest rates, such that the unemployment rate edges up to around 5.8 per cent. Lower rates have also been the basis upon which I've predicted a 10 to 15 per cent "pop" in national house prices over the coming year or so.
This remains my view, and I'm wary to call interest rates much lower even though some economists are falling over themselves to call a cash rate low of 2 per cent.
Indeed, we should not forget that China's economy appears to have stopped decelerating, thanks to an infrastructure boost and some easing in housing restrictions. Most importantly, spot iron ore prices have rebounded strongly from a low of $US90 a tonne to $130 a tonne.
Provided the US avoids its fiscal cliff – as myself and most global investors anticipate – its economic outlook should improve next year, due to a pick-up in the housing sector, a competitive greenback, and cheaper energy prices. I would not be surprised if the US economy grew at a pace of 3 to 4 per cent next year, compared with the current consensus of 2 per cent.
The question is whether a better global economy will quickly boost the domestic economy through, for example, a reversal in mining investment cutbacks or stronger non-mining sentiment. This will also depend on whether stronger global conditions sink or boost the Australian dollar as, these days, it is both a safe haven and commodity currency.
I suspect mining investment won't turn around quickly as, even if the Chinese economy gets better, cost increases and the high dollar remain important challenges. And I still fear supply-side constraints will limit the upside in housing construction.
All that said, my base case view is that the RBA will take on board the recent improvements in the global economy and hold interest rates steady at its next policy meeting in early February. It will want a few more months to see the effect of the lowering in rates on the domestic economy, and especially take a peek at the first official survey of business investment intentions for 2013-14 due to be released on February 28.
The Australian Financial Review


text:
Sock of the Month - December (SK-012) by Lisa Carnahan
Welcome! You are browsing as a guestWould you like to see projects made from this pattern and much more? create a free account What am I missing?
© Lisa Carnahan
Sock of the Month - December (SK-012)
This pattern is available for $5.00 USD buy it now
Holiday motifs adorn the leg of this sock.


text:
Skip Navigation
It is with pleasure I submit the report of my activities of the past year. In the beginning I would like to state, more towns
have been visited, more territory has been covered, and a greater number of people been interviewed than in any year I have
been connected with the Society.
I am quite sure the importance of our historical collection is better known and appreciated than ever before. I am very grateful
to the club women of the state who have co-operated with me in bringing this work before the public. At each of the nine district
club conventions and the Biennial meeting in Bartlesville I was given time to speak of this important work. Many club women
have become members of the Society, and the old Board comprising fifteen women from as many different sections of the state
are a hundred percent membership.
The most important collection I have procured this year is that of Alex Posey, the Creek Indian Poet, who is the foremost
writer of the Five Civilized Tribes to date. He was a newspaper man, and was also interested in historical collections. Since
Mr. Posey's death his widow has had the collection stored. It includes eighty-two articles; clay cooking vessels, baskets,
pottery, beaded work, ball sticks, a scalping knife, wooden spoons and other things of minor importance. They would easily
fill a number of cases if we could properly arrange them.
Mr. Joe Bartles of Dewey, who is the grandson of Charles Journeycake, the late Chief of the Delawares, has loaned to the Society
his interesting collection. This collection consists of a full Indian suit of buck-skin, a beaded hunting bag, which was the
personal property of his grandfather, and some other beaded articles, with one of the most valuable historical things yet
procured, the pipe of peace used by William Penn when the treaty with the Delawares in 1682 was made.
Mr. R. R. Mitchell, of Sulphur, the step-father of Mrs. J. R . Frazier, one of our Board members, loaned a very in-
teresting collection of thirty-five articles. This is a foreign collection from the Philippine Islands. Mr. Mitchell's son
was in the service of the United States there for four years when he made this collection.
Mr. Thomas Alford, a Shawnee Indian and a great nephew of the noted Shawnee Chief Tecumseh, gave us pictures of historic interest,
a pipe of peace that had been in his family over a hundred years. Thomas Alford was the protege of Alice Longfellow when he
was in school in Hampton Roads, Va. He placed in our keeping two letters from her.
One large silver medal given by President Thomas Jefferson to William Harrison, a Choctaw, for meritorious service, the great
grandfather of the present Chief of the Choctaws, William Harrison, is loaned by Eddie McBrayer, a descendant of William Harrison
the first.
Mr. A. F. Chamberlin of Vinita has placed with us a box of 56 small cuts, the first used to illustrate tracts and Bible stories
in the Cherokee language. These were purchased is Philadelphia to be used on the first hand press brought to the state in
From Mr. Will Porter of Tulsa, the soil of Chief Pleasant Porter of the Creek Nation, I procured the loan of a magnificent
war bonnet, which was his father's; it is the most elaborate one we have in our collection.
From Holmes Colbert of Calera, I secured a loan of an old gun used by General Albert Pike, when he made his hunting trips
in company with old Holmes Colbert down in the Chickasaw Nation.
From Mrs. William Settle, of McAlester, I secured the loan of a beautiful large silk flag which was sent by her son from France
in 1919 when he was in the Army of Occupation. The flag is called the Presidential flag.
From some of the Kickapoo Indians I secured a rare old utility bag, made of the fiber of trees; it is unusual because these
fibers are colored before they are woven; the stripes are very regular and of pleasing shades; it is the only one of the kind
we have.
I was asked to assist in assembling a historical exhibit for the biennial meeting of club women which was held in
November at Bartlesville. As things could not be loaned from the Society, I was glad to go with some of the club women to
try to get loans for that special time. Mrs. A. L. Welch, the wife of the Indian Agent at Shawnee, was very enthusiastic over
the work, and through her I met a number of Kickapoo and Pottawatomie Indians. We were very fortunate in getting a Kickapoo
man to make us a miniature flag house. He was willing for me to bring this flag house to the museum for permanent exhibition
after the biennial. This particular piece has attracted no little attention. It takes the place of the skin or cloth tepee
of the Plains Indians. Some of the old Indians still live in them in winter. I have the promise of a bark house in miniature,
when spring comes, for that is the only time of the year they can be made, when the sap is just right.
On my trip to Okmulgee I procured a number of old pictures, among the number are three Chiefs of the Creek Nation, Moty Tiger,
Martin Chicote, and Is-par-noche. On other trips I secured the pictures of John Jumper and Hurlbutta Micco of the Seminoles,
a life sized picture of Judge George W. Scraper of the Cherokees, which is an oil painting.
The great importance of collecting the pictures of the leading men of the different tribes was impressed upon my mind when
the members of our committee attempted to enlarge the pictures of the Chiefs and Governors of the Choctaws and Chickasaws,
and found many of them could not easily be secured, although I had been years assembling them, I had written many letters
in order to secure several, one was sent me from California. After I had lost hope of getting one, I advertised in two different
county papers for a picture I thought should be in that locality.
Through the interest of the Society of the Colonial Dame of Oklahoma, who are ready to assist in historical work, I have been
given the use of a Victrola, traveling case size, and a recording machine. The two cost a hundred dollars. This will greatly
enlarge my work. It is very important that the language of the different tribes should be preserved, as well as the music.
Mr. Thorlow Lieurance, the exponant of Indian music, has a machine like the one bought for my use, and he thinks it quite
easy to handle, but I am hoping to practice on the machine and get satisfactory results this spring
and summer. A number of other things have been added to our collection of minor importance.
In the time given me to make my report I would like to add during the month of August my vacation was spent in New York and
the New England states where I visited twenty-three museums and art galleries. This might seem like a physical impossibility,
but it must be remembered the states are small and near together, and in the larger cities there were several museums. Even
the smaller towns had a special building for their treasures.
I learned much about the work of a great museum. Every courtesy was extended to me. I certainly learned to know more of the
value of things, and to prize more highly our own collection.
Every day I am more convinced of the possibilities of Oklahoma's Historical Society. With the proper housing of our collection
we could make as creditable showing as the majority of museums of other states.
If we cannot get the next legislature to agree to appropriate sufficient money to build an imposing historical building, let
us be willing to have just a unit of one built. Then we can gracefully ask people to help us do things that will make a showing.
Today our department is only a little more than a store room for the most valuable historical possessions of the state of
Oklahoma. Let us prepare to lay our plans for our building before the next legislators are elected. Ever keep in mind we can
make our museum the mecca of the world for students seeking information on Indian subjects.
Respectfully submitted,
Supervisor Indian Department.
Return to top
Electronic Publishing Center |
OSU Home |
Search this Site


text:
> What the hell's a grue?
You must have never played any of the Zork games before. Idiot. Anyway, the grue is basically a killer box-shaped mammal who eats people. They are weak to light and can move faster than you. But it doesn't matte-
> Aw man...all that and they eat me?
Yeah, they eat you before you have a chance to scream.
> Damn...that must be a bug.
That's not a bug, it's a feature. Anyway, enough chitchat -
Would you like to not suck, cheat by loading someone else's save, or give up out of frustration? (Type NOT SUCK, CHEAT, or GIVE UP):


text:
VIDEO: Is Bitcoin a Smart Investment? Only If it Completely Changes, Venture Investor Says
Bitcoin-related startups have sprung up quickly as the digital currency has gained attention. During our Dow Jones video chat Thursday with Rebecca Lynn of Canvas Venture Fund and Asheem Chandna of Greylock, a viewer asked Ms. Lynn—-whose firm has invested in financial services startups including Lending Club–for her thoughts on whether bitcoin is a good investment opportunity.
Check out this short video clip for her answer:
Write to Zoran Basich at email@example.com. Follow him on Twitter at @zoranbasich


text:
SHOWING RECORD: 7 of 45
California Hazelnut
California Hazelnut
Corylus californica
October 22, 1805, along the Deschutes River, Oregon.
Fuzzy, oval-shaped, notched leaves. Blooms in late winter/early spring (February through April), with tiny flowers, about 1 in (2 cm) long. Nuts ready for harvest in summer, about 5/8 in (15 mm) long. Usually a woody deciduous shrub, 5 to 10 ft (2 to 3 m) tall.
Shady slopes, often on the northern side.
Pacific states (Washington, Oregon, California).
Subscribe Online
Your subscriptions help National Geographic conservation efforts
worldwide >>
Double-Crested Cormorant
Harbor Seal
Roosevelt Elk
Sea Otter
Western Common Crow
White Sturgeon
California Hazelnut
California Rhododendron
Dwarf Mountain Fleabane
Eaton's Aster
Mountain Balm


text:
How Southwest Merger Will Affect Ticket Prices
Southwest Buyout of AirTran: Watch Those Ticket Prices
What's the big deal about Southwest's $1.4 billion buyout of fellow budget airline AirTran? Well, there are several outcomes that may affect consumers. On one hand, there will be less competition in the market if airlines keep consolidating (Continental and United are to merge by the end of this year). Fewer players in the field means less incentive for airlines to keep ticket prices low to compete.
On the other hand, the Southwest merger might mean that the company will have a bigger edge against large firms like United because of entry to untapped markets. They will have to compete with the budget airlines, which can drive down the fares of the larger companies. Meanwhile, keep your eye on the developments because great deals may surface from this!


text:
Tarrytown, N.Y. DLC Management Corp. has announced the recent promotion of Sally Krauss to VP real estate transactions.
Krauss is responsible for coordinating and managing the successful completion of DLC's real estate acquisitions, dispositions and all financing transactions. She is also responsible for maintaining environmental compliance with respect to DLC owned and managed properties.


text:
By Matt Bowen, the National Football Post
We know the New York Jets are going to insert Tim Tebow into the game this Sunday vs. the Buffalo Bills, but how will offensive coordinator Tony Sparano utilize his skill set at the QB position? Let's discuss two possible schemes I could see New York carrying in the game plan when the ball is in the red zone: "QB Power" and "Swap Boot."
Take a look at Xs and Os on the chalkboard and then we will break down some key coaching points…
1. QB Power
Personnel: Ace (2WR-2TE-1RB)
Formation: Gun Near Wing Slot
Defensive Scheme: 4-3 "Over" Cover 1 (8-Man Front)
-- Ace personnel with a FB (F) or even a third TE in the game. Use Z "short divide" motion (CB will run with coverage) to create an "option look" at the snap (Tebow will ride Z through the mesh point).
-- Focus on the blocking scheme up front. No different than the 2-Back "Power O" vs. a 4-3 Over Front, the Jets are leading up on the Sam Backer (S) with the FB and pulling the open (weak) side guard up through the hole on the Mike Backer (M). With a double-team on the 3-technique DT (closed side guard will work to the Will Backer), Tebow now has a running lane to get to the second level of the defense.
-- The Z receiver is nothing more than "window dressing." The Jets could hand the ball off ("Jet Sweep"), but this play is designed for Tebow. Load up the closed (strong) of the formation and get the QB in a one-on-one situation vs. the FS at the goal line.
2. Swap Boot
Personnel: Ace (2WR-2TE-1RB)
Formation: Gun Near Wing Slot
Defensive Scheme: 4-3 "Over" Cover 1 (8-Man Front)
-- Same formation, personnel and alignment as the "QB Power" with the Z once again using "short divide" motion into the backfield (CB runs with coverage).
-- Tebow will fake to the Z receiver on the run action. (LBs step to the line of scrimmage). Force the LBs to stick their eyes in the backfield and roll the QB away from the play pass side of the formation.
-- The route breakdown: X on the clear out 9 (fade) route, Y (TE) on the underneath crosser and F on the "swap" release to the Flat.
Check out the entire NFL playbook series.
Nate Davis is a reporter, blogger and editor who's been at USA TODAY since 2000. He has covered the NFL since 2005. No, he did not play quarterback for Ball State. Davis' succession of our esteemed colleague Sean Leahy at The Huddle is considered a Brady-for-Bledsoe swap by most "insiders."More about Nate


text:
NASCIO Wrap-Up: What's Next?Government
I just wrapped up an incredible three days at the National Association of State CIO's (NASCIO) Annual Conference. The event is the largest gathering of state government IT in theRead More
Where 'Digital' and 'People' Meet, a Sweet Spot for BanksExecutive Platform
In a world of roboadvisors, mobile payment apps, and automated processes, do people still matter in banking? I believe the answer is a resounding "Yes!" In fact, as agile, onlineRead More
It's Time to 'Do or Die' in the Growing Global BazaarInnovation
A whopping 59 percent of manufacturers expect their company's strategy to change as a result of real-time information in the next three years. That's in just three years. But whatRead More
Integration, Consolidation, Automation: Why Cisco Cyber Solutions are Essential for CDMGovernment
Cybersecurity for the federal government is increasingly complex. More and more important data is being stored or shared using the Internet, and at the same time, hacks and other cyberattacksRead More
Your Digital Treasure MapFinancial Services
Suppose there is a treasure at the top of a mountain worth $405B. It is more than one person alone can carry back down the mountain, and you have aRead More
The Road to Digital Value Just Got Smoother for BanksFinancial Services
Today's bankers have no shortage of headaches. Agile "fintech" challengers, tech-savvy customers, complex compliance demands, legacy-burdened IT environments — all conspire to keep them up at night. But there isRead More


text:
The heddle is of the greatest importance in the construction of the loom and it is well worth while to understand what it does.
This very ingenious man in 1801 invented a substitute for the heddle.
On each side of the woof in the heddle there is a carrier, B.
The needle, which is longer than the warp is wide, serves also as a heddle in pressing the woof threads together evenly.
With his left hand he works the reed, with his feet he works the heddle.
Scouties may be derived from the skua, though Mr. heddle gives an unpresentable derivation.
Mr. heddle also tells me that the old name of 'Lyars' for the people of Walls was to a great extent replaced by 'Cockles.'
The next movement of the heddle frame crossed the threads over the filling and made a new opening for the return of the shuttle.
Each thread or group of threads of the warp passes through an opening (eye) of a heddle.
Thus with the raising and lowering of the heddle the weft is passed backward and forward and the weaving goes on quite rapidly.


text:
The Mortise Socket is a innovative tool for the Locksmithing and aluminum store front service industry. Many times the mortise lock your working on will get cross threaded, and become extremely tight or hard to remove. If the lock your working on is an expensive high security lock, you can now remove it with the Mortise Socket made by Gator Tools Co.
Corrosion, dirt or grease will not stop this tool from it's task. It will work on the many variations of sizes of locks in today's market. Standard, IC core housings, restricted key housings, just about all types of mortise locks.
This tool will grip a standard mortise lock, you can then attach a 3/8" socket or breaker bar and turn the most stubborn of lock. It will also slide between the mortise lock and many security collars. Plus if there is a need, the tool will break the average Adams-Rite setscrew to remove those expensive locks without damaging the face of the lock.
It comes in retail packaging, instruction and the correct size hex wrench to fit the tool.
NOTES: We did make a couple of improvements with this batch. The main one is the grip length for reaching between the spin collar and the lock. It was lengthened by 50% for the deeper locks. The second was we created more relief for the less expensive ratchets that have square edges, you would not notice unless your tool was not one of the higher end ratchets. It now works with both styles.
Remember; we take your suggestion seriously, you may not see the improvements instantly but they will happen over time.
We were established in 1998, the tools came from being frustrated with no tools to fit the job or the tool just could not do a good enough job for what we needed.
We have had or should I say have many more ideas for tools but many were not feasible to make and or sell, yet these are not the last of
what Gator Tools is about, Keep
an eye out for more innovative
ideas in the future.
Steve, Gator Tools Co.
Just A Note:
Welcome to Gator Tools
Our products are in demand by professional locksmiths who need tools with superior performance and on the job durability. Since our founding, Gator Tools has never shifted focus from our mission, that is: Providing Quality Tools. Gator Tools is the name that spells quality, top-notch durability and professional tools.
It's not just our quality and professional products that make us unique. It also includes a steadfast history of dedicated commitment to our customers. Our tools are supported by unparalleled, experience, knowledge and service to our customers.
All our tools are made right here in the USA.


text:
There I was scrambling for tickets to the movies in Baton Rouge recently — tickets for foreign language films and independent movies, stories that move at a quotidian pace absent the whiff of hyperbole or digital special effects.
The Louisiana International Film Festival was a Whitman's Sampler, absolutely something for everyone and every age. I was only able to attend three features. All three were well-attended, and I hope a nudge to Perkins Rowe to make such features available on a regular, nonfestival basis.
Even on Mother's Day, midday, a foreign language movie made in Poland, shot in black and white, a story about a novice's realizations before taking her vows for the religious community of women, nearly filled the theater.
Hey, don't get me wrong. I can't wait for the next "Star Trek" and "Star Wars," but the opportunity to see something for which you've only read a review, hoping one day it lands on Netflix, was a joy for me and obviously many others.
Thanks to the LIFF for the tremendous effort and to Perkins Rowe for hosting.
Daniel Martin
court reporter
Baton Rouge


text:
Architects dream of building the City on a Hill. Deep down inside, every designer believes that she can make a place that would not just be of the righteous, as St. Augustine hoped, or the Puritan's beacon of doctrinaire faith—but rather a beautiful place. Rarely do architects get to build anything large enough to realize their dreams, and when they do, more often than not, the inhabited reality does not live up to the hoped-for vision.
Carl Laubin, who calls himself an "architectural artist," has assembled such a vision, commissioned by the Notre Dame School of Architecture. Laubin's City on a Hill is not entirely his, however. Rather, it is an assembly of Neoclassical buildings designed by ten years' worth of winners of the Richard H. Driehaus Prize
The painting reminds me not so much of Greece or Rome, however, as of Istanbul, perhaps seen from the back of the Golden Horn looking towards the Hagia Sofia. Colonnaded, pedimented, and gridded buildings tumble down a hill facing a curving waterway. What they do not do is cohere, which is usually one of the arguments classicists make for the virtues of their manner of creating architecture. Laubin has painted the different structures, which range from a small mosque in the foreground, to colleges, office buildings, and private homes, at different scales; and despite some attempts to create a relationship between them, they assert themselves mainly as beautiful objects. Many have porticoes and verandas, opening themselves up to what must be a forgiving climate, though their overall masses appear rather closed.
I was reminded of Laubin's collage, so seductive and wistful, when I was viewing Cyprien Gaillard's videos. In one, a friend dives into the equally alluring pool in front of a housing project designed by Ricardo Bofill outside of Paris ( The Lake Arches, 2007). The water's sweep turns out to be an allusion, and the man emerges with a bloodied nose. Gaillard specializes in tweaking his noses at the utopian impulses of modernism, showing both rebels and frat boys carousing in front of Acapulco resorts ( Cities of Gold and Mirrors, 2005), collaging together photographs of 1960 housing projects with beer labels, or conflating the implosion of the Pruitt-Igoe buildings with Niagara Falls ( Pruitt-Igoe Falls, 2009). He finds beauty not in the posing of perfect structures, but in their decay, destruction, and even inherent violence. His world is rough, falling apart, and more real, but by that token oddly alluring. Perhaps the remoteness of perfection, both in terms of achievability and in its self-enclosed posture, is too alien to us, while the used and the gritty draws out what we want to be. These two impulses come together in the computer-manipulated images of Nicolas Moulin, a French artist who now works in Berlin. After a recent sojourn in Sheffield, England, he photographed the Brutalist housing estates there, then turned them into ghostly places waiting to be reoccupied after some future apocalypse. In another recent project, he replaced the bases of the buildings along the Hausmannian boulevards of Paris with concrete walls, floating their filigreed façades over a zone of exclusion that recalled both prison walls and the abstractions of modern sculpture. In other artworks, he envisions sci-fi structures that extend the reach of the kind of 1970s skyscrapers, apartment blocks, and civic institutions that gave concrete form to social cohesion into monuments memorializing their own brute power.
It is a far way to travel from Laubin's fantasy to Moulin's. But I was reminded that, if you turn away from a view of Istanbul's historic core, you would see many of the kind of structures the latter artist reimagines. I am fascinated by the work of all three of these artists, because all them present that which is inherent, but remains buried, inside built form. They bring out our dreams and our nightmares, and thus put our discipline on the couch. Our repressed desires should perhaps not be built, but we should picture and confront them.


text:
Target: United States Department of Agriculture (USDA)
Goal: Shut down the Reston Zoo following its record of animal abuse and neglect
Roadside zoos are notorious for not always maintaining proper animal welfare standards. One northern Virginia zoo, the Reston Zoo of Vienna, has had a slew of violations. This place made headlines in 2012 when zoo director Megan Mogensen was arrested for drowning an injured wallaby. This isn't the only animal rights issue the zoo has faced.
Exotic animals such as monkeys, zebras, and leopards can be found on site, but the enclosures are completely unfit for these or any other types of animals. The zoo grounds are dingy and unsanitary, and the structures separating the animals are not sturdy or professional. Northern Virginia has seen blizzards and extreme cold over the past few years, and the animals are not properly housed to protect them from extreme weather conditions. Most recently, a spider monkey was found injured and frostbitten, with no professional veterinary help given. Unidentified euthanasia has been found on-site, and employees at the zoo are not trained or certified to handle medical treatment or euthanasia of any kind. All of this adds another level of fright after the infamous drowning incident.
Shockingly, this zoo is still open for business. The zoo director may have been arrested and fined, but this is not enough. The Reston Zoo must be closed permanently, with the animals sent to proper sanctuaries. Please write to the U.S. Department of Agriculture and ask them to revoke the Reston Zoo's license to operate.
Dear U.S. Department of Agriculture,
Your past inspections of the Reston Zoo, a small roadside zoo in Vienna, Virginia, have uncovered multiple animal rights violations. The zoo is unfit for housing animals, so I ask that you permanently remove their license to operate.
Last year, zoo director Megan Mogensen was convicted of animal cruelty when he held a wallaby underwater until it died. Before the drowning, the animal reportedly had a severely injured eye for which no treatment was sought. A monkey was also found with severe frostbite and injuries on his hands and feet, again for which no medical treatment was sought. The USDA also found euthanasia on the zoo grounds during a past inspection, even though the Reston Zoo is not licensed or trained to handle those kinds of materials. The zoo is cramped and dirty, with conditions completely unsuitable for animals.
It is sad to know that this business is still operating. I fear for the future welfare of the animals at this facility. This is why I beg you to re-evaluate the Reston Zoo and remove its license to operate for the sake of these animals.
[Your Name Here]
Photo Credit: ellenm1 via Flickr


text:
Title: A Nobler Race of Men
Author: Aeryn Alexander
Summary: The Enterprise is called upon to perform a mission of mercy for Star Fleet Command. Then things get really complicated: xenophobia, chess, and a terrible disease.
Rating: PG (Mild Language)
Genre: General/ Drama
Author's Note: For once I didn't want to write a shipper. I went out looking for substance. This, such that it is, was what I found. I swear that I did research. But I think my medical and chess terminology and my understanding of distances and location in the Star Trek universe may nevertheless be flawed. Bear with me, please? Read and review.
Special Note: The title may seem sexist, but if I put it in politically correct terms ... it would sound silly.
A Nobler Race of Men
Aeryn Alexander
You shall not change, but a nobler race of men
Shall walk beneath the stars and wander by the shore;
I can not guess their glory, but I think the sky and sea
Will bring to them more gladness than they brought to us of yore.
~ William Roscoe Thayer
Chapter One
Captain Archer had received only a few priority messages from Star Fleet after leaving his native solar system with the Enterprise, and yet somehow most of them came during the middle of the night, forcing him out of bed at the most awkward of hours. That could not be avoided, it seemed. That night, or early morning rather, was no different as Archer tugged a shirt on and scrambled to turn on the lights. As usual it was Admiral Forrest on the screen when he accepted the transmission.
"Admiral." acknowledged the captain, struggling to smooth his disheveled hair.
"I hate to throw this one at you, Jon, and I know you won't like it, but I'm ordering to backtrack a few dozen light years. We need someone out there to perform a mission of mercy for us." explained Forrest candidly as he clasped his hands in front of him. "Have you heard of science station three?" questioned the admiral before Archer could voice his natural objections.
"It was just completed six months ago, right? It's earth's most distant science station, orbiting Ohniaka Four, if I'm not mistaken." answered Archer, naming an outlying star system.
"You are as well informed as ever, I see." commented Forrest.
"I try to keep up as best I can."
"A report came in thirty-six hours ago concerning a sudden epidemic among the scientists and crew stationed there. The facility's medical officer was the first casualty of the deadly disease. Right now, they need supplies and medical personnel or ... we lose forty-seven good people out there." Admiral Forrest informed him solemnly.
"And there's no one else?" questioned Archer, all reservations fading from his mind as he imagined the consequences.
"The Vulcans have acknowledged this as a Star Fleet matter, Jon. They have made it clear that they don't want any of their people infected."
"That bad?"
"Yes, and probably worse."
"I will have to consult with our chief medical officer, but I think we have the necessary supplies. I trust the coordinates of the station are in our database."
"Affirmative on the last part, but you need to rendezvous with the Vulcan cruiser Seleya a few light years from your last reported position."
"Additional supplies?"
Hesitation was written plainly on the face of the admiral. He looked down at his clasped hands and took a deep breath. Whatever he had to say wasn't going to be easy.
"For personnel, captain."
"I assure you that our medical staff ..." began Archer defensively.
"This isn't me talking, Jon. This isn't my opinion. Everyone answers to someone, and the general feeling here is that ... we want a human doctor to treat those people, not one of the galaxy's lesser known and more mysterious species."
Captain Archer felt his face flush with indignation as he told Forrest, "You listen to me. Doctor Phlox has done an exemplary job aboard this ship, and now you want to tell me that he isn't good enough to treat some scientists on a research station? My God, do you realize how insulting, how paranoid, how xenophobic, how unfair that is?"
"Like I said, Jon. It's not my opinion. I've read your reports. Your doctor is good at his job. That he is an alien just doesn't sit well with some people back home. I know he was your choice, and everyone else on the Command Council has respected that choice."
Archer was seething, but taking it out on Admiral Forrest was not going to change a thing. The man was adamant and the decision was made.
"Fine, sir." said the captain bitterly. "When are we scheduled for that rendezvous?" he questioned. He hung his head as he spoke. It was the only time Star Fleet or anyone in it had made him truly ashamed.
"You will be picking up Doctor Zeller in approximately seven hours. The Seleya is probably already at the rendezvous location. I hear that the doctor is an expert on epidemics and plagues. Studied briefly on Vulcan too, if I remember correctly."
"Well, at least we're getting an expert. I would hate to take a less experienced physician to the station." commented Archer acidly.
"I am sorry, Jon, doubly so, but we can't always choose our missions."
After that conversation Captain Archer could not simply go back to sleep. He sat pensively at his desk for the longest time, wondering what, if anything, he should tell his Denobulan chief medical officer. How would he explain to Phlox that prejudice hadn't really been eliminated on earth, that it had just changed into a different variety of the same old thing? It had become human versus alien instead of one race or gender against another. He considered not mentioning it to the doctor. This Doctor Zeller person was supposed to be a specialist. Why not capitalize on that aspect?
"Because someone would eventually tell him why he really can't handle
this crisis." thought Archer dejectedly. "And they might not do it very
tactfully." The captain sighed aloud and began getting dressed. There were
orders to issue, not mention his visit to sickbay, which had to be made
soon. "Well, misery is a communicable disease." he said aloud, having one
of those rare moments when he wished he had become a veterinarian or an
actor and not a star ship captain.
The captain issued the relatively simple orders from his quarters instead of making the trek to the bridge. The Vulcan vessel was not so far away, after all, and Archer didn't want to see the disappointed looks on the faces of the crewmen who guided the ship by night. It was bound to be bitter, despite the nature of the mission, which he divulged to them rather succinctly. Additionally, he would have to go over all of it again with his senior staff in an hour, perhaps less, depending on how the doctor took the news, and Archer did not believe it would be favorably.
The lights of sickbay were rather dim when Captain Archer walked inside. Phlox could rarely be found in his quarters. He never slept. The doctor seemed only to use it as a place to change clothes and store personal items. It reminded Jon very much of his own college dorm room. As Archer stepped into sickbay he saw Phlox playing chess alone by the light of a table lamp. He appeared to be absorbed in the game, propping his chin on one hand as he studied the pieces. His other hand flitted from piece to piece until he finally moved one and looked up from the board.
"Who's winning, doc?" inquired the captain with a smile that did not come easily.
"It may surprise you, but I am." answered Phlox, gesturing for Archer to have a seat.
"Where did you learn to play?" he questioned as he settled into the chair.
"On earth, of course. A friend taught me the game. Many of us in the medical exchange program played chess together when we had the time. They were only to happy for me to learn."
"Are you any good?"
"Before I left, I could hold my own with the other novices, but I could never beat an experienced player." he chuckled. "You don't happen to play, do you, captain?" asked Phlox with a slight gleam in his uncanny blue eyes. Archer strongly suspected that he was sandbagging in order to get him to play.
"From time to time." replied the captain, who felt that delivering the news over a game of chess might be the best available strategy.
"Would you care to play a friendly game then?"
"I would be honored, doctor."
As they set up the board for a game, Phlox shifted the white chess pieces to the captain's side. Archer looked a bit perplexed.
"You think I need the advantage of the first move?" he questioned.
"My friends always deferred to the ranking player, captain." replied Phlox candidly.
"I'm not exactly sure this is what they meant." said Archer, setting up his pieces nevertheless. A lot could be said for having the control of the opening.
When Archer had made his first move, which was rather predictable and conservative, the doctor, his eyes never leaving the board, said, "I know you didn't come here at this hour of the morning to play a game of chess with your chief medical officer, captain."
"True. I came here to talk." Archer acknowledged with considerable frankness.
Finally moving a pawn forward, Phlox looked up at him and commented, "It must be important."
"Everyone has his own definition of important, doctor. This is more ... difficult than important, if you know what I mean." said Archer, matching the move, but struggling to divide his concentration between the game and real issue at hand.
"Complicated then?" questioned Phlox, moving the bishop on his queen's side into the gap in his line of pawns rather quickly. He was clearly thinking somewhat ahead.
"I think that was the word I was looking for." admitted Archer. "I received a priority message from Admiral Forrest at Star Fleet Command this morning." he elucidated further, matching the doctor's move with the bishop on his king's side, but moving one square farther. Both men were playing defensively, though that was not usually the strategy preferred by Archer. Win or lose, he liked a quick game.
"Go on." Phlox told him, studying the board with considerable care before moving a knight out to threaten one of his opponent's pawns, which was well defended.
"We are to rendezvous with a Vulcan cruiser before heading to science station three, which is well behind us. They are experiencing a medical emergency, an epidemic, at the facility, and our mission is ... to see that they are treated." explained Archer, his concentration wavering as he moved the knight on his king's side into a defensive position near his threatened pawn. It appeared, to the doctor, that he was overcompensating.
"It seems relatively simple, captain. But I do have one question. Why are we making a rendezvous with the Vulcan vessel? We are not in need of any medical supplies in so far as I am aware." said Phlox as he moved a pawn forward to free his queen.
"We are taking on a passenger." said Archer, moving his king and rook into a castle position that seemed almost indicative of his mental state. It was as though he were preparing for a sudden onslaught.
"A passenger? Of the Vulcan persuasion I take it." he said before moving his queen out just past the line of pawns, which remained almost unbroken. It was anything but a bold move.
"No, human, actually." said Archer, trying to remain conversational. He paused for a long moment, glad that they had no timer, and moved his remaining knight toward the center of the board. He mentally admonished himself for having gone several years without playing a single game. Chess was nothing like riding a bicycle. Sooner or later it all went away, every skill, every memorized gambit. "A doctor." he added as he set the piece down upon the board.
"Really? This must be quite an emergency if Star Fleet is sending additional personnel all the way out here." said the Denobulan, frowning and sounding uncertain of himself as he castled on his queen's side.
"Is that a legal move?" interjected Archer, hoping to deflect some of the anxiety that he already felt.
"Yes, captain, quite. It was a favorite of one of my teachers who did not like being boxed in, as he put it." replied Phlox, the uncomfortable doubt fleeing his voice at least momentarily.
"Good strategy." Archer agreed. He moved his bishop to threaten the doctor's knight as an additional distraction.
"What sort of catastrophe has happened at this station that they need two doctors and the Enterprise, no less?" inquired Phlox, perhaps more direct than he would have been without that sudden threat of attack on the board. He countered the captain's move by placing his own bishop in a similar position.
"Copycat." muttered Archer, trying to invoke humor, the last refugee of a man in an uncomfortable situation. He edged a pawn out to threaten the doctor's bishop. "I was told that is an epidemic." said Archer, raising his eyes from the board and answering the question put to him.
"Concerning a population of what size?" asked Phlox, taking a deep breath and leaning back in his seat for a better view of the chess board.
"In the neighborhood of fifty scientists and assorted Star Fleet personnel." answered the captain, waiting for his opponent to make his move.
"I see." said Phlox quietly, wagering to sacrifice his bishop in order to capture Archer's knight. It was a rather unequal trade, for Archer wasted no time taking the offending piece.
"It wasn't my call, Phlox." Archer told him.
The doctor looked at him rather oddly and said succinctly, "You have left something out, captain." He moved a pawn forward to threaten the bishop as Archer had done. His concentration was wavering too.
"It isn't easy to explain this without feeling like one of the bad guys." he confessed. Archer had lost all interest in the friendly game of chess that he had wrongly supposed would help him deliver the news. He was only moving pieces as he set into motion the same inglorious exchange that Phlox had made.
"It isn't easy to be the hero all the time." said the Denobulan, taking a white bishop in his hand as he moved forward the bishop that had lain in waiting for so many moves.
"Tell me about it." agreed Archer as he slid his queen forward a few squares.
"Just spit it out, captain." suggested his chief medical officer, who was growing more uncomfortable and weary of the chase. Despite all of that, Phlox still had the presence of mind to threaten Archer's queen with his remaining bishop.
"Admiral Forrest informed me that Star Fleet Command doesn't want you to treat those people because you aren't ... human." Archer told him, absently moving a pawn between the bishop and queen.
It was difficult to gauge the alien doctor's reaction. He nodded slowly, softly that he understood, or rather that he had heard. By no means did he understand in the full meaning of the word. He had worked among humans for a significant amount of time, those serving aboard he Enterprise especially. He almost intrinsically assumed that it was a matter of trust, and he found that particularly wounding. Phlox lifted his eyes slowly from the chess board and looked at Archer.
To the captain's credit, he looked so sufficiently devastated that the expression was easily read by the Denobulan doctor, who uncharacteristically patted his hand before telling him, "I am aware of the chain of command, captain. I know it wasn't your decision to ... exclude me from this ... assignment." Even as he spoke, the captain realized that he was not angry. The doctor was instead phenomenally disappointed. "When will my resignation from this post be required of me?" questioned Phlox solemnly.
"Your resignation, Phlox? No one is asking for you to resign. You were my choice for the position of chief medical officer and no one is questioning that." said Archer.
"But really, captain, isn't it only a matter of time before they do?" he asked his commanding officer with a sad expression on his face.
"Phlox," said Archer firmly, "if they want your resignation, they will have to be prepared to accept mine as well. I won't stand for anyone yanking people out of my command, especially for such backward, xenophobic, and ... and damn dishonorable reasons."
The doctor was surprised at the conviction in the voice of Captain Archer. He was reasonably certain that Archer objected to the orders he had been given, but he was unaware of his commanding officer's underlying strength of character and integrity in such matters. He had no desire to see Archer risk his career on his account, but it was comforting to know that the captain would have been willing to do so out of principle.
"Thank you, sir. Be assured that I will do nothing to stand in the way of this mission. If you would like, we may consider the discussion closed and continue with our game." said Phlox, although the captain could tell that he was still slightly disturbed.
"Of course." agreed Archer, much relieved. He had expected it to go
worse somehow. "Your move." he prompted the doctor.
"That was a terrible game." said Archer, shaking his head as he walked to the lift with Phlox two hours later. "Remind me to practice before I play anyone else."
"You didn't lose, sir." the doctor pointed out.
"It was a stalemate, doc. Nobody won."
When they stopped at the lift, Phlox questioned, "Are you certain that you want me at this briefing, captain?"
Before they had left sickbay, Archer had alerted his senior officers that there would be a briefing in the situation room in twenty minutes. Most of them were already preparing for the beginning of their shift. The rendezvous was only a few short hours away, and he wanted them well informed before that time. The assignment was not at all difficult to understand, but as with everything Star Fleet had ever asked of him, not that they had given him many directives, there was always a hitch. If they had simply asked him to go to science station three and have his own people treat the epidemic, then it would have been an only mildly frustrating mission with a simple resolution. Unfortunately, they had to complicate matters as xenophobic tendencies arose among the upper echelon of Star Fleet Command.
"Of course I want you there. You are my chief medical officer, and, as ever, I'm sure your input will be valuable." Archer told him. "Besides, everyone else would insist that you be there, regardless of circumstances or even orders. You are just as much a part of this crew as anyone else." he assured Phlox.
"Thank you, captain. I knew when I came aboard that the idea of an alien serving onboard a human ship was novel. Even joint fleet operations with the Vulcans had met with limited success. The crew was slow to warm up at first, but they grew accustomed to an alien in their sickbay. Or rather, they are continuing to do so. I appreciate that they have all given me a fair chance, but what you have told me this morning has caused some concern." explained the doctor cautiously.
"The same here, Phlox. It has made me very concerned about the people back home, but I have every confidence in my crew. We've been out here long enough now for me to say that without reservation." said Captain Archer.